Corcept Therapeutics is trading 4.3% down at $91.34 in an isolated pullback following recent sharp gains, despite a lack of new fundamental headlines.
- The move follows a volatile week featuring multiple 4–6% swings, occurring without any fresh company-specific news, earnings, or FDA decisions.
- The stock is currently diverging from a generally positive backdrop across the broader biotech sector this morning.